Emkey Arthritis and Osteoporosis Clinic
Rheumatology
Dr. Ronald D. Emkey, MD
|
|
Give Review
Ronald Emkey works in the field of Rheumatology. He went to Drexel University College of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification", "Fellow" and "Fellow (FACR)". Ronald Emkey is a published physician. He has 41 papers published. The most current publication "Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group." He is registered with Medicare and accepts Medicare payments.
Publications
- Calcium metabolism and correcting Calcium deficiencies.
- Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
- Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid Arthritis. 1989.
- Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
- Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
- Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after Discontinuation of treatment of postmenopausal osteopo...
- Aspirin and renal Disease.
- A case of lymphoproliferative disease presenting as juvenile rheumatoid Arthritis. Diagnosis by synovial fluid examination.
- Low-dose prednisone therapy in rheumatoid Arthritis: effect on vitamin D metabolism.
- Low dose prednisone therapy in rheumatoid Arthritis: a double blind study.
- Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women.
- Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.
- The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
- Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
- The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid Arthritis.
- Prospective 5-year followup of recombinant interferon-gamma in rheumatoid Arthritis.
- Prospective two-year followup of recombinant interferon-gamma in rheumatoid Arthritis.
- Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid Arthritis.
- Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in Vertebral fracture risk: results from the BONE study.
- Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
- Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
- Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
- Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
- Two-year effects of alendronate on bone mineral density and Vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled ex...
- Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.
- Changes in bone mineral density following Discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
- Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
- Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporo...
- Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
- Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
- Ten years'' experience with alendronate for osteoporosis in postmenopausal women.
- Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoArthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory ...
- Safety considerations with bisphosphonates for the treatment of osteoporosis.
- Weekly oral alendronic Acid in male osteoporosis.
- Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
- Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
- Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment.
- Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Iba...
- Quarterly intravenous ibandronate for postmenopausal osteoporosis.
Schools
Hahnemann University
Hahnemann Affil Hosps
Massachusetts General Hospital
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Non-Spinal Nerve Blocks
- Steroid Injection
- View All
Conditions Treated
- Ankylosing Spondylitis
- Ankylosing Vertebral Hyperostosis
- Arthritis
- Bursitis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow
- Fellow (FACR)
Education
-
Massachusetts General Hospital -
Drexel University - Hahnemann University Hospital -
Drexel University College of Medicine
Drug Facts
| NPI NUMBER | 1265592414 | |
| NPPES Provider LastName | EMKEY | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 196103206 | |
| NPPES Provider State | PA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 355.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 39.0 | |
| Percent Opioid Claims | 10.99 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265592414 |
| Last Name Of The Provider | EMKEY |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
Dr. Henry Scovern, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyon J. Park, MD |